Trastuzumab deruxtecan for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Nov 2018: Trial registered, NCT03734029
  2. 27 Dec 2018: Trial started, NCT03734029

The trials

NCT03734029: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

State
Completed
Phase
Phase 3
People
557 taking part
Started
27 Dec 2018
Primary completion
11 Jan 2022
Arms
Trastuzumab deruxtecan
Results
Posted on the registry
Papers
doi:10.1007/s12282-024-01600-7, doi:10.1016/j.annonc.2023.08.003, doi:10.1016/j.critrevonc.2024.104305, doi:10.1038/s41591-025-03981-4, doi:10.1056/nejmoa2203690, doi:10.1093/oncolo/oyaf048, doi:10.1155/tbj/7212120, doi:10.1200/jco.22.02447, doi:10.1200/op.22.00480
  1. 7 Nov 2018: Trial registered
  2. 27 Dec 2018: Trial started
  3. 15 Jun 2023: Trial results posted
  4. 19 May 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Trastuzumab deruxtecan (DS-8201a), Trastuzumab deruxtecan (T-DXd, DS-8201a).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.